Symrise invests in new product development

by Jeff Gelski
Share This:

Symrise AG, Paris, will contribute up to €8 million ($12.6 million) in milestone-related payments toward the development and clinical evaluation of new health and medical food products under a strategic partnership entered into on Dec. 21, 2007, with Cambridge Theranostics Ltd. Symrise announced formation of the partnership on April 9.

Symrise already has invested €2 million in capital in Cambridge Theranostics. The partners will share the profits on products resulting from the collaboration. Founded in 2002 as a spin-off from Cambridge University in England, Cambridge Theranostics specializes in the diagnostics and prophylaxis of cardiovascular diseases.

Cambridge Theranostics will use its proprietary screen to select natural products from Symrise’s libraries of extracts and compounds to identify compounds that may protect against cardiovascular diseases.

Cambridge Theranostics hopes to launch two products by the year 2010. The products will be available via pharmacies, said Dr. G.H. Schmidt, chief executive officer of Cambridge Theranostics.

For more information, visit www.symrise.com.

This article can also be found in the digital edition of Food Business News, April 29, 2008, starting on Page 61. Click
here to search that archive.

Comment on this Article
We welcome your thoughtful comments. Please comply with our Community rules.








The views expressed in the comments section of Food Business News do not reflect those of Food Business News or its parent company, Sosland Publishing Co., Kansas City, Mo. Concern regarding a specific comment may be registered with the Editor by clicking the Report Abuse link.